AWM
EWTX icon

Avior Wealth Management’s Edgewise Therapeutics EWTX Stock Holding History

Avior Wealth Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$145 – 2736
2024
Q1 		$145 Buy
+8
New +$127 ﹤0.01% 3018

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Avior Wealth Management's EWTX Position: Q2 2024 in Review

Avior Wealth Management sold out of Edgewise Therapeutics (EWTX) in Q2 2024, closing a stake of 8 shares — an estimated $145 sold.

Avior Wealth Management first reported a position in EWTX in Q1 2024 and held it in 1 quarter. The position peaked at $145 in Q1 2024. 140 funds tracked by Wall St. Rank hold EWTX as of Q2 2024.

  • Avior Wealth Management reported no remaining Edgewise Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 8 Edgewise Therapeutics shares in Q2 2024, an estimated $145.
  • Avior Wealth Management first reported a position in Edgewise Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Edgewise Therapeutics position peaked at $145 in Q1 2024.
  • 140 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.